From the Journals

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Share

  • 1

    Analysis of 12,245 Crohn's disease patients.

  • 2

    Similar safety profiles noted for biologics and a Janus kinase inhibitor.

  • 3

    Serious infection rates varied, with ustekinumab showing lower GI infection risk.

  • 4

    Venous thromboembolism had low occurrence rates.

  • 5

    Major cardiovascular events were less than 2 per 100 person-years.

  • 6

    Study supported by Crohn's & Colitis Foundation.

  • 7

    Limitations include reliance on claims data and potential residual confounding.

Original Source(s)

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

  • by Doug Brunk

  • February 19, 2026

  • 2 min

Related Content

Income, BMI Linked to Colon Capsule Completion

Danish screening data identify clinical and socioeconomic factors that significantly influence whether colon capsule exams are completed.

Proton Pump Inhibitors and Cancer Risk

Investigators evaluate cancer risk tied to extended acid suppression therapy.

The Unexpected Risks of Liquid Nitrogen Ingestion 

A case report describes gastric perforation following ingestion of a liquid nitrogen–infused drink